AI Doc will Use Scorecards, a proprietary database, and an innovative knowledge management system to help with investment decisions.
Artificial intelligence (AI) has great promise in the healthcare industry. Zoi Capital is pleased to announce the debut of its AI Doc Platform, a cutting-edge internal tool that identifies high-potential use cases and health AI firms.
With AI’s continued promise to improve healthcare, Zoi Capital is dedicated to strategically investing in the upcoming wave of health AI technology. Newly established as a digital health company by Dr. Ronald M. Razmi, a cardiologist trained at the Mayo Clinic and author of “AI Doctor: The Rise of Artificial Intelligence in Healthcare,” Zoi Capital is setting a new standard for private market investing.
Dr. Razmi brings clinical, operational, and investment experience to the table, as does a group of investors and operators in digital health. Co-founders Dr. Ronald M. Razmi and Brian Beeler have a stellar track record, having exited the company through acquisitions and public markets for a combined total of almost $30 billion.
“Given the increasing complexity of sectors such as healthcare and technologies like AI, achieving high returns on capital and ensuring that the best use cases and technologies are funded requires specialization and focus,” said Dr. Razmi.
Zoi Capital has established proprietary scorecards as a scalable and repeatable method for assessing AI solutions that tackle important healthcare concerns. These scorecards assess the use cases that health AI companies are focusing on as well as the businesses themselves. This process guarantees the discovery of high-priority use cases and businesses that successfully overcome adoption constraints.
“The buyers of these technologies have to wade through numerous digital solutions with limited budgets, so they will only choose those that address their most important needs,” said Dr. Razmi. Any health AI investment strategy should start with identifying these use cases. Finding businesses with technology and business models that address technological, clinical, and commercial obstacles will be crucial after the use cases have been identified.
Meticulous assessment by specialists will be the key to success to usher in a new era of deploying capital into the best use cases and companies,” said Brian Beeler, co-founder of Zoi Capital.
The all-inclusive investing tool from Zoi Capital, the AI Doc Platform, consists of:
– Knowledge Management System: This system tracks important unmet needs, industry trends, and new technology in each of the 18 sub sectors that make up the healthcare industry.
– Extensive Database: The database includes information on thousands of digital health businesses, including their technology, use cases, investors, clients, funding, and other details.
– ZoiCare Scorecards for Investment Excellence (Z-Six): These scorecards guarantee that only the use cases that technology buyers deem most important are taken into account for investment and that the adoption hurdles that have impeded the development of numerous promising technologies are being addressed by the companies that have been chosen.
This strategy directs Zoi Capital’s investment choices and offers entrepreneurs a framework for honing and securing the best possible positioning for their inventions in the convoluted healthcare market.
If you would like more information about how Zoi Capital is ideally positioned to lead the charge as the healthcare sector prepares for an AI-driven change, contact them to arrange a time to chat with Dr. Razmi or Brian Beeler.
For additional details, please go to www.zoicap.com.
About Zoi Capital
A themed venture capital company, Zoi Capital focuses on the expanding uses of artificial intelligence in the medical field.
The company’s competitive advantages include cross-functional expertise in practicing medicine, operating successful digital health companies, and investing in medical technologies. The company is led by Dr. Ronald M. Razmi, a former physician, McKinsey consultant, CEO of Acupera, and author of the new book, AI Doctor: The Rise of Artificial Intelligence in Healthcare. Beeler is a former executive in the life sciences industry who has managed multiple corporate venture funds and over $7 billion in transactions.
